Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Identifying epigenetic associations with gestational age and cell type in fetal development
FY 2013-14
Summary
“Identifying epigenetic associations with gestational age and cell type in fetal development”
During the prenatal period, the fetus adjusts its development to suit its early environment. These early-life adaptations affect health- and disease-associated traits in the individual after birth and throughout life. The exact mechanisms that drive this developmental plasticity are not clear, but epigenetic changes are likely a major component. Epigenetic changes are DNA modifications that can affect gene expression without changing the genetic sequence. A major type of epigenetic regulation is DNA methylation, which alters the cytosine bases of DNA.
As the number of fetal epigenetic studies grows, confounding variables have become apparent. Gestational age is a major complication in studies of pregnancy disorders, particularly when these conditions result in pre-term birth. Cell composition is another confounding variable: each type of cell has an epigenetic signature, so overall methylation in a mixed-cell sample is influenced by the different cell types present and their proportions.
My research project is to analyze DNA methylation in placental tissues sampled across gestation and cord blood from pre-term and term births, as well as in different cell types isolated from these samples. The major cell types from 20 placenta samples and 40 cord blood samples will be isolated. Genome-wide DNA methylation will be measured, and sites that show significant methylation differences between cell types or gestational age groups will be identified. The goal is to identify age- and cell-specific DNA methylation patterns.
Fetal epigenetic studies typically use whole cord blood or whole placental tissue samples for analysis, which means they are studying a mixed population of cells. By defining cell-specific DNA methylation, information from mixed-cell samples can be interpreted appropriately. This will be critical for all studies that aim to relate maternal health conditions or environmental factors to offspring health through epigenetic changes.
In the long-term, DNA methylation screening will be used to diagnose maternal and fetal disorders. By identifying methods of accounting for the cell composition and gestational age of the sample, disease screening will be more reliable. This will lead to better treatment of pregnancy disorders, since improved screening protocols will allow for earlier and more accurate disease identification, and thus more appropriate disease management. Early intervention for pregnancy disorders based on more stringent diagnostic procedures will drastically improve maternal and fetal health outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311774
Name
de Goede Olivia M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying epigenetic associations with gestational age and cell type in fetal development
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cord Blood; Dna Methylation; Epigenetics; Fetal Development; Gene Expression And Regulation; Placenta
Abstract
“Identifying epigenetic associations with gestational age and cell type in fetal development”
During the prenatal period, the fetus adjusts its development to suit its early environment. These early-life adaptations affect health- and disease-associated traits in the individual after birth and throughout life. The exact mechanisms that drive this developmental plasticity are not clear, but epigenetic changes are likely a major component. Epigenetic changes are DNA modifications that can affect gene expression without changing the genetic sequence. A major type of epigenetic regulation is DNA methylation, which alters the cytosine bases of DNA.
As the number of fetal epigenetic studies grows, confounding variables have become apparent. Gestational age is a major complication in studies of pregnancy disorders, particularly when these conditions result in pre-term birth. Cell composition is another confounding variable: each type of cell has an epigenetic signature, so overall methylation in a mixed-cell sample is influenced by the different cell types present and their proportions.
My research project is to analyze DNA methylation in placental tissues sampled across gestation and cord blood from pre-term and term births, as well as in different cell types isolated from these samples. The major cell types from 20 placenta samples and 40 cord blood samples will be isolated. Genome-wide DNA methylation will be measured, and sites that show significant methylation differences between cell types or gestational age groups will be identified. The goal is to identify age- and cell-specific DNA methylation patterns.
Fetal epigenetic studies typically use whole cord blood or whole placental tissue samples for analysis, which means they are studying a mixed population of cells. By defining cell-specific DNA methylation, information from mixed-cell samples can be interpreted appropriately. This will be critical for all studies that aim to relate maternal health conditions or environmental factors to offspring health through epigenetic changes.
In the long-term, DNA methylation screening will be used to diagnose maternal and fetal disorders. By identifying methods of accounting for the cell composition and gestational age of the sample, disease screening will be more reliable. This will lead to better treatment of pregnancy disorders, since improved screening protocols will allow for earlier and more accurate disease identification, and thus more appropriate disease management. Early intervention for pregnancy disorders based on more stringent diagnostic procedures will drastically improve maternal and fetal health outcomes.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
de Goede, Olivia M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~